School:School of Medicine
George Follows received his medical degree from Oxford University Medical School and completed his medical and haematology training in Newcastle and Edinburgh, and his PhD at Leeds University. He moved to Cambridge University in 2004 as a Leukaemia Research Fund Senior Clinical Fellow and was later appointed as the Clinical Lead for lymphoma, CLL and clinical trials. He is a former chair of the UK CLL Forum and CLL Guidelines Panel and currently chairs the UK Hodgkin Lymphoma Guidelines Panel.
Professor Follows is the Research Lead for haematology clinical trials at the Cambridge Cancer Trials Centre and is member of the academic faculty of the Anglia Ruskin Medical School as the Visiting Professor of Haematology. He was recently appointed as an Associate Professor of Haematology at the University of Cambridge. He continues to work closely with partners in the pharmaceutical and biotechnology sectors and has authored/co-authored over 100 peer-reviewed papers in different areas of haematological biology and therapeutics in journals, including the New England Journal of Medicine, The Lancet, Journal of Clinical Oncology, Proceedings of the National Academy of Sciences, Cell, and Nature Genetics.
Selected Papers from 2020-2023 (*= clinical trial that led to EMA / FDA drug approval. # = senior / lead author)
*Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study. Munir T, Moreno C, Owen C, Follows G, Benjamini O, Janssens A, Levin MD, Osterborg A, Robak T, Simkovic M, Stevens D, Voloshin S, Vorobyev V, Yagci M, Ysebaert L, Qi K, Qi Q, Parisi L, Srinivasan S, Schuier N, Baeten K, Howes A, Caces DB, Niemann CU, Kater AP. J Clin Oncol. 2023 Jul 20;41(21):3689-3699. doi: 10.1200/JCO.22.02283. Epub 2023 Jun 6.
*Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukaemia. Kater AP, Owen C, Moreno C, Follows G, Munir T, Levin M, Benjamini O, Janssens A, Osterborg A, Robak T, Simkovic M, Stevens D, Voloshin S, Vorobyev V, Ysebaert L, Qin, R, Steele A, Caces D, Niemann C. NEJM Evid 2022 May 13; 1 (7) doi.org/10.1056/EVIDoa2200006
#Guideline for the first-line management of Classical Hodgkin Lymphoma - A British Society for Haematology guideline. Follows GA, Barrington SF, Bhuller KS, Culligan DJ, Cutter DJ, Gallop-Evans E, Kassam S, Osborne W, Sadullah S, Townsend W, Uttenthal BJ, Collins GP; British Society for Haematology.Br J Haematol. 2022 Jun;197(5):558-572. doi: 10.1111/bjh.18083.
#Managing relapsed refractory lymphoma with palliative oral chemotherapy: A multicentre retrospective study. Bulley SJ, Santarsieri A, Lentell IC, O'Sullivan B, Hodson A, Firth O, Sadullah S, Follows AM, Karanth M, Min SY, Fowler A, Russell J, Uttenthal BJ, Hodson DJ, Follows GA. EJHaem. 2022 Sep 2;3(4):1316-1320. doi: 10.1002/jha2.537. eCollection 2022 Nov.
#Incidence and outcomes of post-transplant lymphoproliferative disease after 5365 solid-organ transplants over a 20-year period at two UK transplant centres. Santarsieri A, Rudge JF, Amin I, Gelson W, Parmar J, Pettit S, Sharkey L, Uttenthal BJ, Follows GA. Br J Haematol. 2022 May;197(3):310-319. doi: 10.1111/bjh.18065.
*Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Ferrant E, Wierda WG, Munugalavadla V, Yu T, Wang MH, Byrd JC.Leukemia. 2022 Apr;36(4):1171-1175. doi: 10.1038/s41375-021-01485-x.